Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

Background. Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. Methods. We performed a dose-escalation study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Walsh, Stephen R., Wilck, Marissa B., Dominguez, David J., Zablowsky, Elise, Bajimaya, Shringkhala, Gagne, Lisa S., Verrill, Kelly A., Kleinjan, Jane A., Patel, Alka, Zhang, Ying, Hill, Heather, Acharyya, Aruna, Fisher, David C., Antin, Joseph H., Seaman, Michael S., Dolin, Raphael, Baden, Lindsey R.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3654753/
https://ncbi.nlm.nih.gov/pubmed/23482644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jit105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars